Efficacy of Intravitreal Brolucizumab Switch in Pachychoroid Neovasculopathy
Abstract Introduction This study aimed to evaluate the anatomical and functional outcomes of switching to intravitreally administered brolucizumab (Beovu®, Novartis) in patients affected by pachychoroid neovasculopathy (PNV) who were considered as non-responders to previous anti-vascular endothelial...
Збережено в:
| Автори: | , , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
Adis, Springer Healthcare
2025-07-01
|
| Серія: | Ophthalmology and Therapy |
| Предмети: | |
| Онлайн доступ: | https://doi.org/10.1007/s40123-025-01208-w |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|